|
Accueil > Actualité
AbbVie: EPS down nearly 23% in Q4
(CercleFinance.com) - AbbVie reports adjusted EPS of $2.
16 for Q4 2024, down almost 23% y-o-y, despite sales of $15.1bn, up 5.6% as reported. On an operational basis - i.e., excluding currency effects - revenues rose by 6.1%, notably driven by double-digit growth in its oncology (+12.9%), neuroscience (+19.9%) and ophthalmology (+11.4%) portfolios. With full-year adjusted EPS down 8.9% to $10.12 on revenues that are up 3.7% to over $56.3bn, AbbVie has set a 2025 adjusted EPS target range of $12.12 to $12.32. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
14/02/2025 17:10
Ericssonaccord autour de la formation en Inde 14/02/2025 15:20 AbbViele CEO prendra la présidence du conseil 14/02/2025 15:06 RWEouvre un des plus grands stockages de batteries 14/02/2025 15:00 Pernod RicardWellington MG sous les 5% du capital 14/02/2025 14:31 Bio-UVl'augmentation de capital largement sursouscrite 14/02/2025 14:15 Lexibookla croissance accélère, le titre monte Tous les articles sociétés |
